-
-
-
-
-
-
-
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
-
-
-
-
-
-
-
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
-
-
-
-
-
-
-
Lexaria Bioscience Releases Second Episode of Investor Video Series
-
-
-
-
-
-
-
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
-
-
-
-
-
-
-
Lexaria's Robust Patent Portfolio Continues to Grow
-
-
-
-
-
-
-
Lexaria Awarded Six Additional Patents
-
-
-
-
-
-
-
Lexaria achieves primary endpoint in Phase 1b GLP-1 study
-
461,060 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

